Introduction
============

Video-assisted thoracic surgery (VATS) has become an important part of minimally invasive thoracic surgery. VATS has been proved safe and effective for a large variety of thoracic tumors. A prospective multi-institutional study[@r1] and 2 meta-analyses[@r2]^,^[@r3] of the Cancer and Leukemia Group B revealed VATS lobectomy as an appropriate procedure for early-stage non-small cell lung cancer (NSCLC) compared with open thoracotomy (OT). VATS lobectomy can be performed with low postoperative complications and mortality, and it has a similar 5-year survival rate to that of OT lobectomy, demonstrating similar oncologic efficacies. However, there are controversies on the safety and efficacy of minimally invasive esophagectomy (MIE) for esophageal cancer[@r4]^,^[@r5] and minimal invasive thymectomy for thymoma[@r6]^,^[@r7]. In the present study, the safety and feasibility of VATS pulmonary lobectomy, VATS esophagectomy, and VATS thymectomy were explored.

Materials and methods
=====================

Clinical data
-------------

The medical records of 1,790 consecutive patients were reviewed. These patients underwent VATS pulmonary resections, VATS esophagectomies, VATS resections of mediastinal tumors, and VATS biopsies at the Cancer Institute & Hospital, Chinese Academy of Medical Sciences between January 2009 and January 2012. This study was approved by the Institutional Review Board of the Cancer Institute & Hospital, Chinese Academy of Medical Science. In the same period, 753 lobectomies, 81 esophagectomies, and 41 thymectomies via OTs (OT group) were randomly selected as controls. The clinical variables of paired groups were compared, including age, sex, tumor location, forced expiratory volume in one second (FEV~1~), FEV~1~%, operation time, number of lymph nodal dissection (LND), number of lymph node stations, chest tube duration, morbidity, mortality, and hospital length of stay (LOS). Lung cancer and esophageal cancer staging were carried out according to AJCC 2009 cancer staging[@r8]^,^[@r9]. Thymoma staging were carried out according to Masaoka thymoma staging[@r10].

Surgery
-------

### Pulmonary resection

Techniques of VATS resection for NSCLC have been described in our previous report[@r11] and are outlined as follows. General anesthesia with selective lung ventilation was performed using a double lumen endotracheal tube. Patients were placed in a lateral decubitus position on the operation table. In the VATS group, one thoracoport was initially placed in the seventh or eighth intercostal space on the middle axillary line as observation port. A window (3-6 cm long) was used as the utility incision. The thoracotomy was opened centering around the third or fourth intercostal space with no rib spreading. The third port hole was made based on the location of the tumor. Finally, systematic LND was performed. In the OT group, conventional posterolateral incisions were made for lobectomy (20-30 cm long) and pulmonary wedge resection (10-20 cm long). All specimens were placed in an impermeable bag and removed through the utility incision.

Esophagectomy
-------------

VATS esophagectomy was performed by the method of Luketich *et al*.[@r12]. VATS esophagectomy includes total VATS esophagectomy and hybrid VATS esophagectomy. The former consists of thoracoscopic esophagectomy, laparoscopic gastric preparation, and cervical anastomosis; the latter comprises only thoracoscope surgery. In the OT group, esophagectomy was performed by the Mckeown method[@r13].

Thymectomy
----------

VATS thymectomy was performed by the method of Landreneau *et al*.[@r14] and OT thymectomy via sternotomy, or anterior thoracotomy according to the thymoma location.

Statistical analysis
--------------------

The SPSS software package 13.0 for Windows was used for the statistical analysis. Data were presented as median values (interquartile range) for continuous variables and as percentages for dichotomous variables. Continuous variables were analyzed by the *t*-test or nonparametric test, and categorical variables were analyzed by the χ^2^ test. The significant level was set as a *P* value less than 0.05.

Results
=======

This cohort included 1,790 patients (1,206 males and 584 females) with a median age of 59 years (19 to 86 years). The overall morbidity rate was 2.79% (50/1,790). The complications included severe cardiac arrhythmia requiring medication (*n*=23), respiratory failure (*n*=6), postoperative bleeding (*n*=5), pneumonia (*n*=2), atelectasis (*n*=3), bronchial pleural leakage (*n*=2), bronchial leakage after esophageal surgery (*n*=1), esophageal anastomotic leakage (*n*=2), and wound infection (*n*=6). The mortality rate was 0.28% (5/1,790). Three patients with lung cancer died of acute respiratory distress syndrome, one patient with lung cancer died of pulmonary embolism, and one patient with esophageal cancer died of bronchial leakage.

VATS resections were performed in 1,790 patients, with 33 conversions to OT as a result of pleural adhesion (*n*=11) and intraoperative bleeding \[bleeding of the pulmonary artery branch (*n*=13), pulmonary vein (*n*=5), azygous vein (*n*=2), and innominate vein (*n*=2)\]. The VATS procedures and diagnosis of all patients are summarized in [**Table 1**](#t1){ref-type="table"}.

###### Diagnosis and procedures for 1,790 patients who underwent VATS

  Diagnosis                                                                  Procedure                  Number
  -------------------------------------------------------------------------- -------------------------- --------
  NSCLC                                                                      Lobectomy                  949
  Pneumonectomy                                                              9                          
  Wedge resection                                                            306                        
  Bilobectomy                                                                17                         
  Sleeve lobectomy                                                           5                          
  segmentectomy                                                              16                         
  Biopsy                                                                     8                          
  SCLC                                                                       Lobectomy                  16
  Wedge resection                                                            6                          
  Pulmonary metastasis                                                       Lobectomy                  12
  Wedge resection                                                            63                         
  Benign lung tumor, inflammatory lung disease and congenital lung disease   Lobectomy                  40
  Wedge resection                                                            104                        
  Biopsy                                                                     2                          
  Esophageal cancer                                                          Total VATS esophagectomy   42
  Hybrid VATS esophagectomy                                                  39                         
  Esophageal stromal tumor                                                   Complete resection         5
  Thymoma                                                                    Complete resection         41
  Biopsy                                                                     13                         
  Thymic cancer                                                              Complete resection         4
  Thymic hyperplasia                                                         Biopsy                     7
  Complete resection                                                         21                         
  Germ cell tumor                                                            Complete resection         6
  Biopsy                                                                     1                          
  Mediastinal cyst                                                           Complete resection         5
  Lymphoma, small cell cancer and metastatic tumor                           Biopsy                     6
  Neurogenic tumor                                                           Complete resection         25
  Pleural fibrous tumor                                                      Complete resection         3
  Metastatic pleural tumor                                                   Biopsy                     19

The overall hospitalization and chest tube durations were shorter in the VATS lobectomy group than in the OT lobectomy group, but the operation time was longer in the VATS lobectomy group. There was no significant difference in the morbidity and mortality rates between the two groups. There was no significant difference in the number of LND and number of lymph node stations between the VATS lobectomy and OT lobectomy groups for pathological stage I and II NSCLC. However, there was a significant difference in the number of lymph node stations in pathological stage III between the two groups ([**Table 2**](#t2){ref-type="table"}).

###### Comparison of short-term outcomes between VATS lobectomy and open lobectomy for NSCLC (*n*=1702)

  Characteristics              VATS group (*n*=949)   OT group (*n*=753)           *P*
  ---------------------------- ---------------------- -------------------- -------------
  Age (years)                  59 (52-65)             57 (52-61)           \<0.001
  Male (%)                     583 (61.4)             439 (58.3)           0.195
  History of smoking (%)       368 (38.8)             315 (41.8)           0.213
  Charlson scores              0 (0-1)                0 (0-0)              \<0.001
  Tumor location (%)                                                       0.998
     LUL                       232 (24.4)             189 (25.1)           
     LLL                       167 (17.6)             132 (17.5)           
     RUL                       273 (28.8)             212 (28.2)           
     RML                       58 (6.1)               47 (6.2)             
     RLL                       219 (21.3)             173 (23.0)           
  FEV~1~ (L)                   2.38 (2.05-2.89)       2.60 (2.37-3.01)     \<0.001
  FEV~1~ (%)                   70.4 (69.2-88.9)       91.7 (82.1-101.0)    \<0.001
  Operation time (h)           2.6 (2.0-3.3)          2.7 (2.3-3.2)        0.074
  No. of LND                                                               
     Stage I                   16 (11-24)             15 (10-21)           0.647
     Stage II                  20 (15-24)             23 (19-25)           0.055
     Stage III                 19.0 (10.5-30.0)       21.0 (18.0-24.0)     0.139
  No. of station of LND                                                    
     Stage I                   6 (4-7)                5 (4-6)              0.122
     Stage II                  6 (5-7)                6 (5-7)              0.679
     Stage III                 4 (3-4)                6 (5-6)              \<0.001
  Histology (%)                                                            0.003
     Squamous cell carcinoma   226 (23.8)             228 (30.3)           
     Adenocarcinoma            672 (70.8)             47.5 (63.1)          
     Others                    51 (5.4)               50 (6.6)             
  Chest tube duration (d)      4.0 (4.0-5.5)          5.0 (4.0-6.0)        \<0.001
  Pathological stage (%)                                                   0.520
     I                         683 (72.0)             493 (65.5)           
     II                        141 (14.9)             140 (18.6)           
     III                       125 (13.2)             120 (15.9)           
  Morbidity (%)                23 (2.4)               25 (3.3)             0.303
  Mortality (%)                4 (0.4)                2 (0.3)              0.699
  Hospital LOS (d)             15.0 (13.5-18.0)       17.0 (15.0-20.0)     \<0.001
  Postoperative LOS (d)        9.0 (8.0-11.0)         11.0 (9.0-12.0)      0.205

VATS, video-assisted thoracic surgery; OT, open thoracotomy; LUL, left upper lobe; LLL, left lower lobe; RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; FEV1, forced expiratory volume in one second; LND, lymph node dissection; LOS, length of stay.

In the VATS esophagectomy group, there were 42 esophagectomies and 39 hybrid esophagectomies. No significant difference was found in the number of nodal dissection, chest tube duration, morbidity rate, mortality rate, or hospital LOS between the VATS esophagectomy and open esophagectomy (OE) groups. Patients who underwent VATS esophagectomies had longer operation time ([**Table 3**](#t3){ref-type="table"}).

###### Comparison between the short-term outcomes of VATS esophagectomy and OE for esophageal cancer (*n*=162)

  Characteristics              VATS group (*n*=81)   OE group (*n*=81)           *P*
  ---------------------------- --------------------- ------------------- -------------
  Age (years)                  60.0 (54.0-66.0)      56.0 (52.0-60.5)    0.004
  Male (%)                     49 (60.5)             53 (65.4)           0.626
  Charlson scores              0 (0-0.0)             0 (0-0.0)           0.638
  Tumor location (%)                                                     0.620
     Upper                     33 (40.7)             30 (37.0)           
     Mid                       40 (49.4)             39 (48.1)           
     Lower                     8 (9.9)               12 (14.8)           
  Operation time (h)           6.7 (5.0-8.0)         5.0 (3.0-5.0)       \<0.001
  Number of nodal dissection   15 (9-23)             16 (13-18)          0.172
  Chest tube duration (d)      5 (3-7)               4 (3-7)             0.154
  Pathological stage (%)                                                 0.931
     I                         25 (30.9)             23 (28.4)           
     II                        33 (40.7)             35 (43.2)           
     III                       23 (28.4)             23 (28.4)           
  Morbidity (%)                12 (14.8)             11 (13.6)           1.000
  Mortality (%)                1 (1.2)               1 (1.2)             1.000
  Hospital LOS (d)             18 (15-21)            21 (16-21)          0.833

VATS, video-assisted thoracic surgery; OE, open esophagectomy; LOS, length of stay.

There was no significant difference in the chest tube duration, morbidity rate, mortality rate, and hospital LOS between VATS thymectomy and open thymectomy for thymoma. Patients who underwent VATS thymectomies had longer operation time than those who underwent OT thymectomy. The median tumor size of 5.4 cm in the VATS group was comparable with that of 4.5 cm in the open thymectomy group ([**Table 4**](#t4){ref-type="table"}).

###### Comparison between the short-term outcomes of VATS thymectomy and open thymectomy for thymoma (*n*=82)

  Characteristics           VATS thymectomy group (*n*=41)   OT thymectomy group (*n*=41)       *P*
  ------------------------- -------------------------------- ------------------------------ ---------
  Age (years)               52 (41-61)                       52 (40-57)                     0.419
  Male (%)                  23 (56.1)                        16 (39.0)                      0.184
  Charlson scores           0 (0-1)                          0 (0-0)                        0.007
  Operation time (h)        2.1 (1.3-3.0)                    2.0 (1.7-2.0)                  0.038
  Chest tube duration (d)   3 (3-4)                          3 (3-4)                        0.343
  Tumor size (cm)           5.4 (4.0-7.5)                    5 (3.5-6.0)                    0.081
  Myasthesia gravis         4 (9.8)                          5 (12.2)                       1.000
  Masaoka staging (%)                                                                       0.269
     Stage I                17 (41.5)                        23 (56.1)                      
     Stage II               24 (58.5)                        18 (43.9)                      
  Morbidity (%)             0 (0)                            4 (9.8)                        0.116
  Mortality (%)             0 (0)                            0 (0)                          1.000
  Hospital LOS (d)          12 (9-15)                        12 (9-15)                      0.650

VATS, video-assisted thoracic surgery; OT, open thoracotomy; LOS, length of stay.

Discussion
==========

With the advances in endoscopic equipment and surgical skills, VATS has become a useful modality for the management of many intrathoracic diseases. Compared with VATS esophagectomy and VATS dissection of mediastinal tumors, VATS lobectomy is increasingly being performed for early lung cancer worldwide. Hence, there is a tendency for VATS lobectomy to replace most open lobectomy procedures[@r15].

In this VATS lobectomy series (NSCLC group), the postoperative morbidity and mortality rates were 2.4% and 0.4%, respectively. The postoperative LOS and chest tube duration were shorter in the VATS lobectomy group than in the OT lobectomy group, comparable with previous reports[@r2]^,^[@r3]. Swanson *et al*.[@r16] also showed similar results. Hence, the safety of VATS lobectomy is comparable with that of OT lobectomy for operable NSCLC with reduced LOS and chest tube duration.

No significant difference was found in the number of LND and number of LND stations between VATS lobectomy and OT lobectomy for pathological stage I and II NSCLC. Watanabe *et al*.[@r17] and Scott *et al*.[@r18] demonstrated similar results. On the other hand, there was a significant difference in the number of LND stations for pathological stage III in the present study. Dellinger *et al*.[@r19] found that the number of N~2~-level LND in the VATS lobectomy group is less than that in the OT group, and attributed the deficit in LND to the learning curve. Recently, Kim *et al*.[@r20] found that for clinical stage I NSCLC patients with pathologic N~1~ or N~2~ disease after VATS lobectomy, survival was comparable with that after lobectomy through a thoracotomy. Therefore, based on literature and our experience, VATS has similar efficacy and results in similar long-term survival to OT for clinical early-stage NSCLC patients planned for lobectomy.

Despite considerable improvements in esophageal cancer staging and patient selection, generally high complication rates encourage the search for alternative operative techniques that can achieve similar cure rates but with less morbidity. With this objective, MIE has been introduced under the form of various combinations of thoracoscopy and laparoscopy. The VATS approaches for the treatment of esophageal cancer are currently still considered investigational and under clinical evaluation[@r4]^,^[@r5]^,^[@r21]^,^[@r22]. The indication for MIE is similar to that for OT, which is resectable esophageal cancer[@r4].

This study showed no significant difference in the number of nodal dissection, chest tube duration, morbidity rate, mortality rate, and hospital LOS between the VATS esophagectomy and OE groups. However, the operation time was longer in the VATS esophagectomy group. Zingg *et al*.[@r21] reported similar results. On the other hand, the morbidity rate after operation was still moderately high in our series; 7 patients had complications, including severe arrhythmias requiring medication in 3 cases, wound infection in 1 case, esophageal anastomotic leakages in 2 cases, and bronchial leakage in 1 case which resulted in the only death in our series. Luketich[@r12] reported 27 anastomotic leaks accounting for 11.7% of the 222 patients, and tracheal tear was found in 2 patients. The overall mortality was 1.4% (3/222). Nguyen *et al*.[@r22] reported 8 cases of gastrointestinal leaks and 4 cases of anastomotic intrathoracic leaks in 104 MIE operations, and the in-hospital mortality was 2.9%. Tan *et al*.[@r23] reported 5 cases of anastomotic leaks in 36 MIE patients. However, no peri-operative death occurred because the esophagogastric anastomosis was in the neck. All these results showed that MIE can be safely performed only in large medical centers, although devastating results can occur after MIE.

Currently, there are two MIE techniques, including totally VATS esophagectomy and hybrid VATS esophagectomy. Although there is no evidence of a specific advantage of one technique over another[@r5], minimally invasive Ivor-Lewis esophagectomy (thoracoscopy plus laparoscopy) with two-field lymph node dissection in patients with resectable esophageal cancer is the preferred approach in Pittsburgh Medical Center, the biggest MIE center for esophageal cancer in the USA[@r4]. With the development of surgical techniques, similar to total VATS pulmonary lobectomy becoming the gold standard for the surgical treatment of lung cancer requiring lobectomy[@r24], total MIE may become the gold standard for the surgical treatment of resectable esophageal cancer in the near future.

Neurologic fibroma is safe for VATS dissection for benign mediastinal tumors, such as thymic cyst. The most common indication for VATS thymectomy is the treatment of myasthenia gravis[@r25]. The controversies surrounding the indication of VATS thymectomy for thymoma[@r6]^,^[@r7]^,^[@r26]^,^[@r27] has two aspects, namely, tumor size and tumor staging. The median tumor size of thymoma was 5.4 cm in the VATS group, which was comparable with the 4.5 cm in the open thymectomy group in our series. Li  *et al*.[@r27] reported that resections of noninvasive bulky solid thymomas by complete thoracoscopy are feasible and safe. The mean tumor size was 7.1 cm (5 to 10 cm) and patients survived 5 to 75 months without evidence of recurrence or metastasis. Pennathur *et al*.[@r7] reported that 40 early-stage patients (14 of stage I and 26 of stage II) received thymectomy (open thymectomy for 22 patients and VATS for 18). No significant difference was found in the estimated recurrence-free and overall 5-year survival rates (83%-100%) between the two groups. The median tumor size of thymomas was 4 cm (3 to 8 cm), and all patients (4 of stage I and 7 of stage II) underwent complete dissection. Tumor size alone is not absolute contraindication. Therefore, based on literature and our results, VATS thymectomy for early-stage thymoma (Masaoka stage I and II) is safe and feasible.

In the present study, the VATS lobectomy patients were younger than those in the studies reported by Swanson *et al*.[@r16] and Scott *et al*.[@r18], in which the median ages were 66 and 72 years, respectively. On the other hand, the median age of 59 years in our lobectomy series was comparable with that in other medical centers in China. Yang *et al*.[@r28] reported an average age of 59 years for patients receiving lobectomy in a multi-center series of 600 consecutive cases of VATS lobectomy. For thymoma patients, the median age of 52 years in our series was within the range (44 to 63 years) of previous reports[@r7]^,^[@r29].

The operation time in the VATS group (including VATS esophagectomy and VATS thymectomy) was longer than that in the OT group. Learning curves are important in these procedures. Osugi *et al*.[@r30] reached a plateau of VATS esophagectomy after performing 34 procedures. Toker *et al*.[@r31] demonstrated that a thoracic surgeon must perform at least 30 VATS thymectomies to reach a success rate of 80%.

The median postoperative LOS of 9 days in the VATS lobectomy group in this study was longer than that in the studies of Swanson *et al*.[@r16] and Scott *et al*.[@r18], in which the median LOS values were 6.1 and 4.5 days, respectively. In the multi-center VATS lobectomy series of Yang *et al*.[@r28] in China, the median LOS was 11.8 days, which was comparable to that in the present report.

This study had several limitations. First, it was retrospective. Second, only short-term outcomes were observed and long-term survival needs further evaluation. Finally, the results were obtained from one cancer center and may not be generalized to other medical centers.

Conclusions
===========

For early-stage (I/II) NSCLC patients who underwent lobectomy, VATS had similar short-term outcomes to those of OT approach. For pulmonary wedge resection, VATS was superior to the OT approach, with shorter chest tube duration and hospital LOS. For resectable esophageal cancer, VATS esophagectomy had similar morbidity and mortality to those of OT esophagectomy. There is a tendency for total MIE (thoracoscopy plus laparoscopy) to become the preferred approach for resectable esophageal cancer. VATS thymectomy for Masaoka stage I and II thymoma is feasible and safe, and tumor size is not contraindicated. Longer follow-ups are needed to determine the oncologic equivalency of VATS lobectomy, pulmonary wedge resection, esophagectomy, and thymectomy for thymoma versus OT.
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